Johnson and Johnson 2014 Annual Report Download - page 10

Download and view the complete annual report

Please find page 10 of the 2014 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

health of women and children include our work in support
of the Millennium Development Goals. In addition, in 2014
we expanded programs using mobile technology as a
way to disperse health information to new and expectant
mothers in South Africa and India and announced a
global partnership with Save the Children that has
the potential to help improve the survival and healthy
development of millions of children under age 5 over
the next three years.
Our commitment to transforming the lives of patients
and communities includes our contributions of
approximately $1 billion in products and cash last year
in support of over 500 programs that address major
health-related issues in local communities in more than
50 countries around the world.
and waste production throughout our products’ lifecycles.
For example, we continue to integrate and expand
our EARTHWARDS® approach to drive continuous
sustainability improvements and innovation across
our businesses. To date, more than 73 products have
gained EARTHWARDS® recognition, ahead of our
2015 goal.
We remain committed to enhanced transparency and
engagements with stakeholders that serve to improve the
health of patients and drive improved clinical outcomes.
We announced an extended agreement with the Yale
Open Data Access (YODA) Project to provide access to
clinical trial data for pharmaceutical and medical device
products, setting new industry standards by being the first
company to do so. Our ongoing efforts to improve the
2014 BUSINESS HIGHLIGHTS
† Non-GAAP measure. See “Reconciliation of Non-GAAP Financial Measures” on pages 70 and 71 of this Annual Report.
* Operational measures exclude the impact of currency translation.
** IMS MIDAS data as of Q3 2014 (growth versus previous year (moving annual total) in local currency dollars)
NOTE REGARDING FORWARDLOOKING STATEMENTS
The Chairman’s Letter and Business Highlights section contain forward-looking statements relating to, among other things, business
strategy, performance and expectations for product development. The reader is cautioned not to rely on these statements and should
review the section “Cautionary Factors That May Affect Future Results” on page 19 of this Annual Report for important information
about these statements, including the risks, uncertainties and other factors that could cause actual results to vary materially from the
assumptions, expectations, and projections expressed in any forward-looking statements. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information or future events or developments.
VIII • 2014 BUSINESS HIGHLIGHTS